All Articles

On November 16, 2023, the FDA approved capivasertib (Truqap; AstraZeneca Pharmaceuticals), in combination with fulvestrant, for the treatment of hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer in patients with ≥1 PIK3CA, AKT1, or PTEN genetic mutations, as detected by an FDA-approved test. Read More ›

On November 15, 2023, the FDA approved repotrectinib (Augtyro; Bristol Myers Squibb), a ROS1 tyrosine kinase inhibitor (TKI), for the treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) associated with ROS1 fusion. Read More ›

On November 16, 2023, the FDA approved a supplemental new drug application for enzalutamide (Xtandi; Astellas Pharma and Pfizer), an androgen receptor signaling inhibitor, for the treatment of nonmetastatic, castration-sensitive prostate cancer with biochemical recurrence (BCR) at high risk for metastasis (high-risk BCR). Read More ›

On November 9, 2023, the FDA approved Flowflex COVID-19 Antigen Home Test (Flowflex; ACON Laboratories), the first over-the-counter (OTC) antigen test for COVID-19 for use by individuals aged ≥14 years. Read More ›

Adjuvant treatment options for premenopausal women with hormone receptor–positive breast cancer now include endocrine therapy and ovarian function suppression (OFS) based on clinicopathologic characteristics that determine composite risk of recurrence. Read More ›

Understanding the role of the estrogen receptor (ER) in the pathogenesis of breast cancer has led to the development of treatment options that lead to reduced estrogen levels. In addition, the expression level of ER can serve as a prognostic indicator for disease recurrence and treatment response. Read More ›

With the availability of approaches for preserving fertility and ovarian function, physicians should be prepared to discuss the impact of chemotherapy on fertility and ovarian function with patients newly diagnosed with breast cancer in order to personalize treatment plans based on patients’ goals. In the modern era, an increasing number of women are opting to delay pregnancy. Read More ›

Measuring estradiol levels during ovarian function suppression (OFS) remains debatable. It can be argued that the assessment of estradiol levels is clinically irrelevant since general OFS can be achieved with the currently available approaches, and the outcomes of OFS trials are not based on estradiol levels. However, a variety of factors may lead to ovarian escape (OE). Read More ›

Despite the fact that 51% of patients with breast cancer have reported fertility concerns, evidence indicates that fertility preservation methods are underutilized. Read More ›

Studies have demonstrated that at least half of patients undergoing treatment for breast cancer are concerned about potential infertility and demonstrate interest in becoming pregnant after the conclusion of their treatment. Even those not interested in pregnancy seek to avoid ovarian insufficiency and early menopause, which can negatively impact patients’ quality of life—an important treatment goal. Read More ›